The NP Screen™ detects the earliest form of nasopharyngeal cancer by identifying and quantifying carcinoma in-situ cells. Our screening tool does this by using Quantitative polymerase chain reaction (Q-PCR), which pinpoints cells with EBV DNA integration, a marker for NPC tumors. This technology is so sensitive that it can detect the earliest stage of NPC when it is not even visible above or under the skin.
Collection – NP Screen™ directly samples from the nasopharynx where the cancer is first formed. In the nasopharynx, submucosal tumour cells will migrate outward to the surface, which allows NP Screen™’s mildly abrasive brush to pick up the necessary samples for analysis— a mere 2000 to 5000 cells. This contrasts past screening tools that analyze blood samples for DNA material and dead tumour cells from rapidly growing tumors.
Preservation – The cells collected can be preserved within a proprietary solution at room temperature for up to 30 days without degradation. This permits the most accurate analysis possible. In comparison, DNA analysis of blood samples can be hindered by DNA’s 15 minute half-life in the blood stream in which immediately fragments.
QPCR – NP Screen™ utilizes the quantitative result Q-PCR process to pinpoint the cell samples with NPC tumor markers, EBV DNA integration. By amplifying DNA samples collected, Q-PCR analyzes the sample with a clinically validated interpretation. This allows NP Screen™ to detect the earliest stage of NPC (carcinoma in-situ stage 0) with 99% accuracy.